PhoenixBio Co., Ltd. AI Stock Analysis
Want to see JP:6190 full AI Analyst Report?
PhoenixBio Co., Ltd. (6190) AI Stock Analysis
PhoenixBio Co., Ltd.
(TSE/TYO:6190)
The overall score of 54 reflects a company with a stabilizing financial foundation that is under significant market pressure. The primary strength is a robust balance sheet with low debt. However, this is offset by major weaknesses: a persistently bearish technical trend with the stock price below all key moving averages, and a very high P/E ratio that raises valuation concerns given volatile earnings. The recent return to profitability is a positive sign, but it has not yet translated into consistent cash flow or positive market momentum.
PhoenixBio Co., Ltd. (6190) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 1.02B
- Dividend Yield
- ―
- Average Volume (3M)
- 9,920
- Price to Earnings (P/E)
- 67.9
- Beta (1Y)
- 0.60
- Revenue Growth
- -4.57%
- EPS Growth
- ―
- Country
- Japan
- Employees
- 55
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
PhoenixBio Co., Ltd. Business Overview & Revenue Model
Company Description
PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featurin...
PhoenixBio Co., Ltd. Financial Statement Overview
Summary
Financial performance is mixed. The balance sheet is a clear strength with low debt and a solid equity base (Score 76). However, income (Score 61) and cash flow (Score 57) scores are lower due to historical volatility and weak cash conversion, despite a recent return to profitability. The overall financial foundation is stabilizing but not yet consistent.
Income Statement
61PositiveBalance Sheet
76PositiveCash Flow
57Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.57B | 1.57B | 1.54B | 1.72B | 2.12B | 1.32B |
| Gross Profit | 1.20B | 1.19B | 1.11B | 1.20B | 1.56B | 727.79M |
| EBITDA | 129.60M | 116.52M | -396.12M | 87.94M | 537.42M | -305.81M |
| Net Income | 125.23M | 125.23M | -445.65M | 26.38M | 493.33M | -387.97M |
Balance Sheet | ||||||
| Total Assets | 2.19B | 2.19B | 2.31B | 2.74B | 3.02B | 2.28B |
| Cash, Cash Equivalents and Short-Term Investments | 1.15B | 1.15B | 1.15B | 1.39B | 1.56B | 1.33B |
| Total Debt | 486.64M | 486.64M | 565.36M | 723.93M | 1.13B | 1.04B |
| Total Liabilities | 640.05M | 640.05M | 944.82M | 946.58M | 1.50B | 1.45B |
| Stockholders Equity | 1.55B | 1.55B | 1.37B | 1.80B | 1.51B | 828.15M |
Cash Flow | ||||||
| Free Cash Flow | 0 | 56.42M | -94.24M | -118.08M | 265.12M | 9.63M |
| Operating Cash Flow | 0 | 68.86M | -73.00M | -79.31M | 277.49M | 16.40M |
| Investing Cash Flow | 0 | -13.75M | -27.98M | 115.36M | -156.34M | -6.97M |
| Financing Cash Flow | 0 | -88.01M | -128.00M | -244.88M | 86.63M | -34.66M |
PhoenixBio Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6190, the sentiment is Negative. The current price of 249.00 is below the 20-day moving average (MA) of 277.65, below the 50-day MA of 300.62, and below the 200-day MA of 384.01, indicating a bearish trend. The MACD of -16.73 indicates Positive momentum. The RSI at 33.59 is Neutral, neither overbought nor oversold. The STOCH value of 41.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6190.
PhoenixBio Co., Ltd. Peers Comparison
Overall Rating
JP:619054Neutral
JP:234244Neutral
JP:497842Neutral
JP:777442Neutral
JP:777626Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 54Neutral | JPY 1.02B | 67.93 | ― | ― | -4.57% | ― | |
| 44Neutral | JPY 3.32B | -178.76 | ― | ― | 8.53% | 97.93% | |
| 42Neutral | JPY 11.43B | -24.60 | ― | ― | -8.23% | -48.10% | |
| 42Neutral | JPY 26.80B | -74.58 | ― | ― | 17.05% | 10.47% | |
| 26Underperform | JPY 6.42B | -5.26 | ― | ― | -49.43% | -3.77% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:6190 | PhoenixBio Co., Ltd. | 249.00 | -157.00 | -38.67% | |
| JP:2342 | Trans Genic Inc. | 182.00 | -44.00 | -19.47% | |
| JP:4978 | ReproCELL Inc. | 106.00 | -52.00 | -32.91% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 648.00 | 170.00 | 35.56% | |
| JP:7776 | CellSeed Inc. | 155.00 | -225.00 | -59.21% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 16, 2026
